Tag
The DECISION trial demonstrated that discontinuation of low-dose digoxin in heart failure patients optimized on guideline therapy leads to increased heart failure events and clinical deterioration, supporting cautious withdrawal decisions.
Early catheter ablation in atrial fibrillation patients with prior ischemic stroke reduces major adverse cardiovascular events and improves neurological and cognitive outcomes compared to medical therapy, according to a multi-center retrosp
An indirect comparison shows tirzepatide significantly reduces major adverse cardiovascular events and mortality in type 2 diabetes patients, highlighting its potential for improving cardiovascular outcomes.
Empagliflozin consistently reduces major cardiovascular events, heart failure hospitalizations, and mortality across diverse sociodemographic and cardiovascular risk groups in older adults with type 2 diabetes, with especially pronounced ab
Among older adults receiving CAR-T therapy, 5.8% experienced major adverse cardiovascular events (MACE), associated with increased mortality. Pre-existing cardiac conditions heightened risk, underscoring the need for cardiovascular monitori
This updated meta-analysis of 28 RCTs reveals significant reductions in cardiovascular events and mortality with intracoronary imaging-guided PCI versus angiography-guided PCI, highlighting the importance of lesion and geographic factors in
Digitalis glycosides reduce cardiovascular death or worsening heart failure events in HFmrEF and HFrEF patients over a median of 36–37 months, supported by randomized trials and meta-analyses highlighting their role in select heart failure
The LIFE-Preserved model accurately predicts short-term and lifetime risks of heart failure hospitalization or cardiovascular death in HFpEF patients, enabling tailored clinical risk stratification and improved management.
GLP-1 receptor agonists reduce mortality and cardiovascular events more effectively than SGLT2 inhibitors in serious mental illness (SMI), with early benefits and consistent effects across bipolar disorder, major depression, and schizophren
This study introduces a causal endotype-based classification of myocardial infarction, revealing distinct underlying mechanisms and clinical outcomes beyond the traditional type 1/type 2 framework, potentially improving MI diagnosis and man
This review synthesizes evidence on physician-focused financial incentives for hypertension control, highlighting nuanced impacts on clinical decisions, documented blood pressure control, and cardiovascular outcomes, with a focus on both ov
Elevated endogenous insulin and insulin resistance independently predict progression of diastolic dysfunction and increased cardiovascular mortality, highlighting early metabolic dysregulation as a target to prevent heart failure with prese
A predefined subanalysis of EAST-AFNET 4 shows early rhythm control safely reduces cardiovascular events in recently diagnosed AF patients with CKD, with a trend toward greater benefit in this high-risk group.
Hypothyroidism increases the incidence of CABG and is linked to higher risks of postoperative complications, heart failure, stroke, and major adverse cardiovascular events, highlighting the importance of preoperative thyroid function optimi
A novel risk score incorporating COPD and graded renal dysfunction improves prediction of one-year mortality post-TAVI, showing excellent internal validity but requiring external validation before clinical use.
A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascula
This study leverages Mendelian randomization to demonstrate that genetically elevated BMI is associated with increased mortality and adverse cardiovascular outcomes in heart failure, irrespective of ejection fraction status, underscoring po
This study uses Mendelian randomization to show that higher genetically predicted BMI is associated with increased all-cause mortality and cardiovascular events in heart failure patients, regardless of ejection fraction status.
This pooled analysis found that CPAP may lower cardiovascular event risk mainly in patients with high-risk obstructive sleep apnoea, especially those with stronger heart-rate surges or greater oxygen deprivation during sleep.
CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen’s efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432
